Vanda Pharmaceuticals Inc. (VNDA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-01-08

Key Insights

Vanda Pharmaceuticals received a letter from the FDA stating that its supplemental New Drug Application (sNDA) for HETLIOZ® for the treatment of jet lag disorder cannot be approved in its current form.
This is a setback for Vanda as the company had previously announced a collaborative framework with the FDA to conduct an expedited re-review of the sNDA by January 7, 2026.
Investors should closely monitor Vanda's next steps in addressing the FDA's concerns and any potential impact on the company's financial performance and growth prospects.

Want the newest filings?

This analysis covers the filing from 2026-01-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2025-12-31

Vanda Pharmaceuticals has received FDA approval for its new drug NEREUS TM (tradipitant) for the prevention of vomiting induced by motion, which could expand the company's product portfolio and revenue potential.
The approval of NEREUS TM represents a significant milestone for Vanda Pharmaceuticals, as it adds a new therapy to the company's lineup and diversifies its revenue sources.
Investors will likely view this FDA approval positively, as it demonstrates Vanda's ability to successfully develop and bring new products to market, which could drive future growth and shareholder value.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.